bmx-001
Small moleculeexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02655601)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Hypopharyngeal Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 2
- Mouth Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Radiation Exposure · Phase 1
- Rectal Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomatitis · Phase 2
Mechanism of action
- Unspecified targetOTHER
Metalloporphyrin antioxidant (antitumor, radioprotectant)
PMEL other
- Unspecified targetAntioxidant
Antioxidant
Chemistry & pharmacology
- Mol. weight
- 1253.57 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297271 ↗
Also known as
- bmx-001
- bmx-001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06620029 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2025 | BioMimetix Pharmaceutical, Inc., Duke University |
| NCT06532279 | Phase 2 | Oct 30, 2024 | NRG Oncology |
| NCT05254327 | Phase 2 | Aug 15, 2022 | BioMimetix Pharmaceutical, Inc., National Cancer Institute (NCI), University of Nebraska |
| NCT04607642 | Phase 2 | Jan 31, 2021 | BioMimetix Pharmaceutical, Inc., Duke University, University of California, San Francisco |
| NCT03608020 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2018 | BioMimetix Pharmaceutical, Inc., Duke University, National Cancer Institute (NCI) |
| NCT03386500 | Phase 1 | Nov 28, 2017 | BioMimetix Pharmaceutical, Inc., University of Nebraska |
| NCT02990468 | Phase 1 | Apr 19, 2017 | BioMimetix Pharmaceutical, Inc., Duke University, University of Colorado, Denver |
| NCT02655601 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | BioMimetix Pharmaceutical, Inc., Duke University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioMimetix Pharmaceutical, Inc. | For profit | 7 | 5 | 2 | 2016 |
| Duke University | Academic/Hospital | 5 | 0 | 2 | 2016 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2018 |
| University of Nebraska | Academic/Hospital | 2 | 2 | 2 | 2017 |
| NRG Oncology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1